Literature DB >> 32026265

Clinical importance of late gadolinium enhancement at right ventricular insertion points in otherwise normal hearts.

Chrysanthos Grigoratos1, Adriana Pantano2, Maria Meschisi3, Raffaella Gaeta4, Lamia Ait-Ali5, Andrea Barison6, Giancarlo Todiere6, Pierluigi Festa6, Gianfranco Sinagra2, Giovanni Donato Aquaro6.   

Abstract

Late gadolinium enhancement (LGE) has an established prognostic value in otherwise normal hearts, when detected with a subepicardial or intramyocardial pattern; nevertheless, the clinical relevance of isolated right ventricular insertion point (RVIP) LGE is yet to be defined. From a retrospectively identified cohort of 2000 consecutive patients undergoing CMR, we selected 420 patients according to study's inclusion and exclusion criteria (270 males, mean age 38 ± 17 years) with apparently normal hearts: besides 36 patients with non-ischemic pattern LGE (other-LGE group), we found isolated RVIP-LGE in 44 patients and absence of LGE (no-LGE group) in 340 patients. Clinical follow-up was performed for a median of approximately 6 years. Primary composite endpoint included cardiac death, resuscitated cardiac arrest, and appropriate implantable cardiac defibrillator shock. Prevalence of cardiac events was significantly lower in RVIP-LGE than in the other-LGE group (p = 0.006). Kaplan Meier curve analysis demonstrated no significant differences between patients with RVIP-LGE and no-LGE for the primary endpoint. On contrast, patients with other-LGE had worse prognosis than those with RVIP-LGE or no-LGE (p < 0.0001). RVIP-LGE in subjects without additional evidence of cardiac damage does not convey worse prognosis when compared to subjects without LGE and it should not be considered a marker of disease. Its diagnostic and prognostic significance is to be considered irrelevant.

Entities:  

Keywords:  Cardiomyopathy; Junctional fibrosis; Late gadolinium enhancement; Magnetic resonance imaging; Prognosis; Right ventricular insertion points

Mesh:

Substances:

Year:  2020        PMID: 32026265     DOI: 10.1007/s10554-020-01783-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  19 in total

1.  Understanding late gadolinium enhancement in pulmonary hypertension.

Authors:  William M Bradlow; Ravi Assomull; Philip J Kilner; J Simon R Gibbs; Mary N Sheppard; Raad H Mohiaddin
Journal:  Circ Cardiovasc Imaging       Date:  2010-07       Impact factor: 7.792

2.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

3.  Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study.

Authors:  Giovanni Donato Aquaro; Giovanni Camastra; Lorenzo Monti; Massimo Lombardi; Alessia Pepe; Silvia Castelletti; Viviana Maestrini; Giancarlo Todiere; Piergiorgio Masci; Gabriella di Giovine; Andrea Barison; Santo Dellegrottaglie; Martina Perazzolo Marra; Gianluca Pontone; Gianluca Di Bella
Journal:  J Magn Reson Imaging       Date:  2016-08-29       Impact factor: 4.813

Review 4.  Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR).

Authors:  Matthias Vöhringer; Heiko Mahrholdt; Ali Yilmaz; Udo Sechtem
Journal:  Herz       Date:  2007-03       Impact factor: 1.443

Review 5.  Myocardial Fibrosis in Athletes.

Authors:  Freek R van de Schoor; Vincent L Aengevaeren; Maria T E Hopman; David L Oxborough; Keith P George; Paul D Thompson; Thijs M H Eijsvogels
Journal:  Mayo Clin Proc       Date:  2016-10-06       Impact factor: 7.616

Review 6.  Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis.

Authors:  Chrysanthos Grigoratos; Gianluca Di Bella; Giovanni Donato Aquaro
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

7.  Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.

Authors:  Katherine C Wu; Robert G Weiss; David R Thiemann; Kakuya Kitagawa; André Schmidt; Darshan Dalal; Shenghan Lai; David A Bluemke; Gary Gerstenblith; Eduardo Marbán; Gordon F Tomaselli; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2008-06-24       Impact factor: 24.094

8.  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.

Authors:  J A McCrohon; J C C Moon; S K Prasad; W J McKenna; C H Lorenz; A J S Coats; D J Pennell
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

9.  A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging.

Authors:  Kristopher W Cummings; Sanjeev Bhalla; Cylen Javidan-Nejad; Andrew J Bierhals; Fernando R Gutierrez; Pamela K Woodard
Journal:  Radiographics       Date:  2009 Jan-Feb       Impact factor: 5.333

10.  Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure.

Authors:  Pier Giorgio Masci; Constantinos Doulaptsis; Erika Bertella; Alberico Del Torto; Rolf Symons; Gianluca Pontone; Andrea Barison; Walter Droogné; Daniele Andreini; Valentina Lorenzoni; Paola Gripari; Saima Mushtaq; Michele Emdin; Jan Bogaert; Massimo Lombardi
Journal:  Circ Heart Fail       Date:  2014-03-19       Impact factor: 8.790

View more
  6 in total

1.  Association between myocardial fibrosis, as assessed with cardiac magnetic resonance T1 mapping, and persistent dyspnea after pulmonary embolism.

Authors:  Jostein Gleditsch; Øyvind Jervan; Mazdak Tavoly; Oliver Geier; René Holst; Frederikus A Klok; Waleed Ghanima; Einar Hopp
Journal:  Int J Cardiol Heart Vasc       Date:  2021-12-28

Review 2.  The right ventricular involvement in dilated cardiomyopathy: prevalence and prognostic implications of the often-neglected child.

Authors:  Paolo Manca; Vincenzo Nuzzi; Antonio Cannatà; Matteo Castrichini; Daniel I Bromage; Antonio De Luca; Davide Stolfo; Uwe Schulz; Marco Merlo; Gianfranco Sinagra
Journal:  Heart Fail Rev       Date:  2022-03-22       Impact factor: 4.654

3.  Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study.

Authors:  Rui Meng; Heshui Shi; Jia Liu; Yukun Cao; Kuikui Zhu; Sheng Yao; Mei Yuan; Xiangchuang Kong; Xiaoming Liu; Yumin Li; Yue Cui; Xiaoyu Han; Xiaoyue Zhou
Journal:  Quant Imaging Med Surg       Date:  2022-10

Review 4.  Myocardial fibrosis in athletes-Current perspective.

Authors:  Łukasz A Małek; Chiara Bucciarelli-Ducci
Journal:  Clin Cardiol       Date:  2020-03-19       Impact factor: 2.882

Review 5.  Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Athletes with Premature Ventricular Beats.

Authors:  Giulia Brunetti; Alberto Cipriani; Martina Perazzolo Marra; Manuel De Lazzari; Barbara Bauce; Chiara Calore; Ilaria Rigato; Francesca Graziano; Riccardo Vio; Domenico Corrado; Alessandro Zorzi
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

6.  Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers.

Authors:  Rebecca K Hughes; Claudia Camaioni; João B Augusto; Kristopher Knott; Ellie Quinn; Gabriella Captur; Andreas Seraphim; George Joy; Petros Syrris; Perry M Elliott; Saidi Mohiddin; Peter Kellman; Hui Xue; Luis R Lopes; James C Moon
Journal:  J Am Heart Assoc       Date:  2021-07-27       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.